- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05158829
COVID-19 Antibody Responses In Cystic Fibrosis (CAR-CF)
Coronavirus disease 2019 (COVID-19) which is caused by the virus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in people with CF (pwCF) is due to enhanced infection prevention practices or whether pwCF have protective genetic/immune factors. This study aims to prospectively assess the proportion of pwCF, including both adults and children with CF who have evidence of SARS-CoV-2 antibodies over a two-year period. This study will also examine whether pwCF who have antibodies for SARS-CoV-2 have a different clinical presentation and what impact this has on their CF disease. The proposed study will recruit pwCF from paediatric and adult CF centres throughout the United Kingdom. Serological testing to detect antibodies will be performed on blood samples taken at month 0, 6, 12, 18 and 24 with additional time-points if bloodwork is available via normal clinical care. Clinical data on, lung function, CF-related medical history, pulmonary exacerbations, antibiotic use, and microbiology and vaccination receipt, will be collected during routine clinical assessments.
Associations will be examined between socio-demographic and clinical variables and serologic testing. The investigators will also examine the effects of SARS-CoV-2 infection on clinical outcomes and analyse end-points to explore any age-related or gender-based differences, as well as subgroup analysis of outcomes in lung-transplant recipients and pwCF receiving cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies. As pwCF receive COVID-19 vaccination the investigators will perform a comparison of the development and progression of anti-SARS-CoV-2 antibodies in pwCF following natural infection and vaccination SARS-CoV-2 over time.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
This is a prospective, longitudinal cohort study in people with Cystic Fibrosis (pwCF) that involves repeated serial sampling of participants. This study design was chosen to provide comprehensive information on SARS-CoV-2 seroprevalence changes over time and the subsequent clinical impact on pwCF. The study will be conducted at participating CF centres over a 3-year period. Study participants will include paediatric and adult pwCF. Participating investigators can enrol all eligible pwCF over a 12-month period. Participants are then followed up for 24 months. Participants will donate blood samples at their routine clinic visits. Blood samples will be collected at Day 0 (baseline), at Months 6, 12, 18 and 24 (to coincide with routine clinical reviews). Additional blood samples will be taken opportunistically every time the participant visits the clinic for blood draws. These blood samples could be related to, routine care, annual review visits, pulmonary exacerbations (PEx), CF complications or when initiating new treatments (e.g. CFTR modulators).
Serum from blood samples will be shipped to a central laboratory (Queen's University Belfast) for standardized measurement of SARS-CoV-2 antibodies.
Alongside the blood samples the investigator will also collect clinical data from the patient's health records and will input this data into the case report form (CRF). Clinical data will be collected in conjunction with routine care visits, according to local clinical practice. Investigators will collect data elements from information routinely recorded in the patients' medical records. Data will be collected at baseline, month 6, 12, 18 and 24 as per the study schedule, and at additional blood sampling timepoints as previously explained above. Data collection will include routine data available from CF clinic follow-ups including background demographic information, CF medical history, medications, exacerbation information, sputum microbiology and clinical and lung function parameters. Information on SARS-CoV-2 infection history and vaccine receipt will also be collected.
The maximum follow-up duration of participation in the study for each patient will be 24 months. This study duration (24-month follow-up) is justified as it provides sufficient time to observe changes in antibody prevalence over the course of the COVID-19 pandemic as well as sufficient time to determine long term clinical outcomes for pwCF who are SARS-CoV-2 seropositive. Furthermore, the investigators anticipate the 2-year study follow-up period will provide sufficient time to observe the impact of vaccination on antibody levels given that a number of vaccines are now commercially available.
The investigators will compare the level of antibody responses between natural COVID-19 infection and vaccination in pwCF and how this varies over time. This will be achieved by analyzing seroprevalence and antibody levels according to natural infection and vaccination status and according to time of sample post infection or post vaccination, if known.
Optional Study sample collection:
For participants who consent, a second blood sample will also be drawn into Ethylenediamine tetraacetic acid (EDTA) tubes (plasma). Consent to this optional study sample would allow this sample and any remaining serum (following antibody testing) to be stored for future analysis and allow further research to be carried out on related studies to COVID-19 and CF.
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Carla Colombo, MD
- Número de teléfono: 0255032460
- Correo electrónico: carla.colombo@unimi.it
Ubicaciones de estudio
-
-
-
Firenze, Italia
- Reclutamiento
- Centro Regionale toscano di riferimento per la fibrosi cistica- Azienda Ospedaliero- universitaria Mayer
-
Contacto:
- Giovanni Taccetti
-
Genova, Italia
- Reclutamiento
- Istituto G. Gaslini Centro Fibrosis Cistica
-
Contacto:
- Carlo Castellani, MD
-
Milan, Italia
- Activo, no reclutando
- UOS Fibrosi Cistica dell'Adulto, Fondazione IRCCS Ca' Granda Ospedale Policlinico
-
Orbassano, Italia
- Aún no reclutando
- Centro Regionale per la Fibrosi Cistica Azienda Ospedaliero-Universitaria San Luigi Gonzaga
-
Contacto:
- Barbara Messore, MD
-
Roma, Italia
- Aún no reclutando
- Ospedale Pediatrico Bambino Gesù di Roma Divisione Dipartimento di Pediatria
-
Contacto:
- Alessandro Fiocchi, MD
-
Torino, Italia
- Aún no reclutando
- Centro Regionale per la Fibrosi Cistica Piemonte-Torino Sezione Infantile presso AOU Città della Salute e della Scienza
-
Contacto:
- Elisabetta Bignamini, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Consenting people with cystic fibrosis of any age, genotype, transplant status and disease severity
Exclusion Criteria:
- Refusal to give informed consent
- Contraindication to venepuncture. Participants already enrolled in a clinical trial are eligible for enrollment in this study. Inclusion in CAR-CF should not preclude enrollment in other observational clinical trial studies or clinical trials of an investigational medicinal product (CTIMP).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Evaluar la seroprevalencia del SARS-CoV-2
Periodo de tiempo: Período de 3 años (que comprende un período de inscripción de 1 año y un seguimiento de 2 años)
|
Evaluar la seroprevalencia del SARS-CoV-2 en una cohorte de personas con fibrosis quística, seguidas longitudinalmente durante un período de 3 años (que comprende un período de inscripción de 1 año y un seguimiento de 2 años).
[Marco de tiempo: período de 3 años (que comprende un período de inscripción de 1 año y un seguimiento de 2 años)] Examinar las asociaciones entre la seropositividad del SARS-CoV-2, los síntomas clínicos y los resultados clínicos en una cohorte de personas con enfermedad quística fibrosis
|
Período de 3 años (que comprende un período de inscripción de 1 año y un seguimiento de 2 años)
|
Asociación de seropositividad al SARS-CoV-2, síntomas clínicos y resultados clínicos en pwCF
Periodo de tiempo: Período de 3 años (que comprende un período de inscripción de 1 año y un seguimiento de 2 años)
|
incidencia de COVID-19 sintomático durante el período de estudio y gravedad; proporción de pwCF seropositivos con exacerbación posterior de la FQ en comparación con pwCF que son seronegativos; tasa de mortalidad en pwCF con al menos un resultado seropositivo en comparación con pwCF que son seronegativas.
|
Período de 3 años (que comprende un período de inscripción de 1 año y un seguimiento de 2 años)
|
Longitudinal comparison of the detection, including level and duration, of anti-SARS-CoV-2 antibodies in pwCF following natural infection and SARS-CoV-2 vaccination.
Periodo de tiempo: 3-year period (comprising a 1-year enrollment period and a 2-year follow-up)
|
3-year period (comprising a 1-year enrollment period and a 2-year follow-up)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Almacenamiento de muestras para futuros análisis.
Periodo de tiempo: previsto entre 5 y 10 años
|
Almacenamiento de muestras para futuros análisis sobre el impacto de la respuesta inmune COVID-19 en personas con fibrosis quística
|
previsto entre 5 y 10 años
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Carla Colombo, MD, Milan CF Center, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CAR-CF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Fibrosis quística
-
Peking Union Medical College HospitalReclutamientoFibrosis Retroperitoneal IdiopáticaPorcelana
-
San Gerardo HospitalTerminadoFibrosis pulmonar idiopática | Fibrosis cardiaca | Fibrosis ArterialItalia
-
Assistance Publique - Hôpitaux de ParisReclutamientoFibrosis Retroperitoneal IdiopáticaFrancia
-
Peking Union Medical College HospitalReclutamientoFibrosis Retroperitoneal IdiopáticaPorcelana
-
Peking Union Medical College HospitalReclutamiento
-
Peking Union Medical College HospitalReclutamientoFibrosis Retroperitoneal IdiopáticaPorcelana
-
University of ParmaDesconocidoFibrosis Retroperitoneal Idiopática | Fibrosis retroperitoneal perianeurismática | Periaortitis crónicaItalia
-
Hospital de Clinicas de Porto AlegreDesconocidoFibrosis quística | Exacerbación pulmonar de fibrosis quística | Fibrosis quística en niños | Fibrosis quística con exacerbaciónBrasil
-
Olympus Corporation of the AmericasGeisinger ClinicTerminado
-
Johns Hopkins UniversityGuerbetAún no reclutandoFibrosis miocárdicaEstados Unidos